StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report released on Wednesday. The brokerage issued a sell rating on the stock.

Bio-Path Price Performance

BPTH opened at $0.78 on Wednesday. The business has a 50 day simple moving average of $0.89 and a 200-day simple moving average of $1.08. Bio-Path has a 12 month low of $0.59 and a 12 month high of $9.99.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.